> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# GSK Jemperli Trial Meets Endpoint
- URL: https://www.fdaweb.com/gsk-jemperli-trial-meets-endpoint/
- Published: 2023-10-30T12:00:00.000Z
- Updated: 2026-09-14T14:14:40.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5155670

GSK says a Phase 3 trial evaluating its Jemperli (dostarlimab) in adult patients with primary advanced or recurrent endometrial cancer met its primary endpoint of overall survival (OS). The trial (RUBY/ENGOT-EN6/GOG3031/NSGO) is investigating dostarlimab plus standard-of-care chemotherapy (carboplatin and paclitaxel), followed by dostarlimab as a single agent, compared to placebo plus chemotherapy followed by placebo.

“A clinically meaningful OS benefit was observed in both prespecified subpopulations in the trial: mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) and mismatch repair proficient (MMRp)/microsatellite stable (MSS) patient subgroups,” the company says. Previously, the trial met its other primary endpoint of progression-free survival, demonstrating a 72% and 36% reduction in the risk of disease progression or death observed in the studied population, it adds.

Jemperli is described as a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2\. It is currently indicated in combination with carboplatin and paclitaxel, followed by single agent Jemperli for treatingadult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient.